Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | AKT2 | P31751 | 1/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 8/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17913008 | 0.86 | ROCK2 (0.65) | ROCK2PKMROCK1TNIK | |
| SCHEMBL20985823 | 0.81 | ROCK2 (0.63) | ROCK2ROCK1AKT2TNIKJAK1 | |
| SCHEMBL19643936 | 0.79 | ROCK2 (1.00) | ROCK2ROCK1AKT2TNIK | |
| SCHEMBL19643172 | 0.79 | ROCK2 (1.00) | ROCK2ROCK1TNIK | |
| SCHEMBL28267553 | 0.78 | ROCK2 (0.64) | ROCK2ROCK1AKT2TNIKJAK1 | |
| SCHEMBL17913016 | 0.77 | PKM (0.66) | ROCK2PKMROCK1TNIK | |
| SCHEMBL16915088 | 0.76 | PKM (0.67) | ROCK2PKMROCK1 | |
| SCHEMBL17912995 | 0.76 | ROCK2 (0.65) | ROCK2PKMROCK1TNIK | |
| SCHEMBL17912992 | 0.75 | PKM (0.79) | ROCK2PKM | |
| SCHEMBL13362788 | 0.75 | ROCK2 (0.67) | ROCK2ROCK1AKT2TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406426-B | Cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2020-11-20 | — | — | CN | claimed |
| CN-107406426-B | Cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2020-11-20 | — | — | CN | disclosed |
| EP-3242873-B1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3242873-B1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10123993-B2 | Cyclic ureas as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3242873-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016112236-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016112236-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123993-B2 | Cyclic ureas as inhibitors of rock | MYLK, ROCK1, UACA | ROCK2 4/4885PKM 1485/4885ROCK1 2/4885 |
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | MYLK, ROCK1, UACA | ROCK2 4/4885PKM 1485/4885ROCK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.